Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 6Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Polycystic Ovary Syndrome 2Vaginal Atrophy 1Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Sarcoma, Synovial 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Metastatic Breastcancer 1Insulin Resistance 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Endocrine System Diseases 1Depression 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Anxiety Disorders 1Anus Neoplasms 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Dehydroepiandrosterone × Clear all
NCT00006219 2011-08-04

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Mayo Clinic

Phase 2 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡